| 摘要 |
Cpds. of formula (I) and their pharmaceutically acceptable salts are new, (where R1=uracilyl, cytosinyl, hypoxanthinyl, adeninyl or carbamoyl; R2=N-contg. unsatd. heterocycle, opt. substd. by oxo or lower alkyl; R3=H or a phosphono gp.). - 8 cpds. (I), e.g. 1-((2R,6R)-3,5-dihydroxy-6- hydroxymethyl-4-(2-pyrimidinyl)- morpholin-2-yl)-uracil and 9-((2R,6R)-3,5-dihydroxy-6- hydroxymethyl-4-(6-purinyl)- morpholin-2-yl)-hypoxanthine are specifically claimed.
|
